+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 80Years
All Genders
Healthy Volunteers
ID06725693

Evaluation of 68Ga18F-Exendin 4 PETCT Imaging for Diagnosis of Primary and Metastatic Lesions in GLP-1 Receptor-Related Diseases

Led by Tianjin Medical University · Updated on 2026-09-08

500

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the usefulness of 68Ga18F-Exendin 4 positron emission tomographycomputed tomography PETCT scans for diagnosing primary and metastatic lesions in patients with various GLP-1 receptor-related diseases. It involves patients who may have suspected, newly diagnosed, or previously treated malignant tumors related to GLP-1R. The study focuses on measuring how well this imaging technique detects these lesions. Participants receive a single intravenous injection of 68Ga18F-Exendin 4 and then undergo PETCT imaging within a specified timeframe. The study analyzes the uptake of the tracer in lesions by calculating the maximum standardized uptake value SUVmax. It assesses diagnostic accuracy by measuring sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. During the study, participants undergo the PETCT scan and related assessments. Researchers collect imaging data to evaluate the tracer uptake and diagnostic efficacy within 30 days. Participants provide informed consent before enrollment. The primary outcome measure is the standardized uptake value, with diagnostic efficacy as a secondary measure. The study includes adults aged 18 to 80 and monitors safety and imaging results throughout the study period.

CONDITIONS

Brief Title

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

Research Team

Q

Qiusong Chen, MD

H

Haonan Yu, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here